Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 10, 2001, Pages 4666-4673

  Diamanti Kandarakis, Evanthia ^a,b   Spina, Giovanna ^a   Kouli, Chryssa ^a   Migdalis, Ilias ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ENDOTHELIN 1; GLUCOSE; INSULIN; METFORMIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; FEMALE; GLUCOSE UTILIZATION; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; MAJOR CLINICAL STUDY; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RISK MANAGEMENT;

EID: 0034748334     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.10.7904     Document Type: Article

References (54)

1. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: A prospective study
2. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile
3. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach
4. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome
5. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
6. Prospective analysis of the insulin-resistance syndrome (syndrome X)
7. Risk factors for coronary artery disease in lean and in obese women with polycystic ovary syndrome
8. Coronary heart disease risk factors in women with polycystic ovary syndrome
9. Cardiovascular risk in women with polycystic ovarian syndrome
10. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization
11. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women
12. Mortality of with women polycystic ovary syndrome at long-term follow-up
13. Early activation of vascular endothelium in non-obese, non-diabetic essential hypertensive patients with multiple metabolic abnormalities
14. Insulin resistance, its consequences and coronary heart Disease must we choose on culprit?
15. Cardiac flow velocity in women with the polycystic ovary syndrome
16. Vascular reactivity is impaired in genetic females taking high dose androgens
17. Clinical signs of androgen excess as a risk factor for coronary artery disease
18. Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
19. Endothelilum-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease
20. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen
21. Molecular biology and biochemistry of the endothelin
22. Plasma endothelin-1 levels in obese hypertensive and normotensive men
23. Circulating endothelin-1 levels in obese patients with the metabolic syndrome
24. Endothelial cell function in diabetic microangiopathy
25. Elevated plasma endothelin in patients with diabetes mellitus
26. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men
27. Endothelin: Emerging role in diabetic vascular complications
28. Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities
29. Plasma irmmunoreactive endothelin in essential hypertension
30. Increase plasma endothelin level in patients with essential hypertension
31. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension
32. Microvascular and macrovascular reactivity is reduced in subjects at a risk for type 2 diabetes
33. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome
34. Polycystic ovary syndrome is associated with endothelian dysfunction
35. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
36. Polycystic ovaries: A common finding in normal women
37. 21-Hydroxylase deficiency in female hyperandrogenism: Screening and diagnosis
38. Relation of body fat distribution to metabolic complications of obesity
39. The relative contribution of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women
40. Clustering of metabolic factors and coronary heart disease
41. Coronary risk factors, endothelian function and atherosclerosis: A review
42. Impaired vasoconstriction to endothelin-1 in patients with NIDDM
43. Increased plasma levels of endothelin-1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia
44. Insulin modulates circulating endothelin-1 levels in humans
45. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans
46. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo
47. Insulin stimulates production and secretion of endothelin from bovine endothelial cells
48. Obesity/insulin resistance is associated with endothelial dysfunction
49. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, wile facilitating normal menses and pregnancy
50. Patterns of coronary heart disease morbidity and mortality in the sexes. A 26-year follow up of the Framingham population
51. Testosterone worsens endothelial dysfunction associated with hypercholesterolemia and environmental tobacco smoke exposure in male rabbit aorta
52. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness
53. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1
54. Estradiol-17β affects estrogen receptor distribution and elevates progesterone receptor content in baboon aorta